Recent clinical advancements in the management of HER2-positive breast cancer are refining treatment strategies for both early-stage and metastatic disease. New research highlights the efficacy of targeted therapy combinations in improving patient outcomes, including survival rates and disease-free intervals, by integrating agents such as trastuzumab, pertuzumab, and newer antibody–drug conjugates.
Phase 3 Studies Test Maintenance and Neoadjuvant Therapies
M. Tolaney. Additionally, maintenance therapy regimens are being tested to enhance durability of response, such as the use of tucatinib in combination with trastuzumab and pertuzumab, evaluated in phase 3 studies led by E. Hamilton. Loibl, as well as neoadjuvant approaches for high-risk patients in randomized, open-label, multicenter phase III trials headed by N. Harbeck.
Adjuvant Treatment Protocols
Standardized adjuvant therapy following surgery continues to evolve to reduce the risk of recurrence. For patients with operable HER2-positive primary breast cancer, the addition of pertuzumab to a regimen of chemotherapy and trastuzumab has been shown to reduce the risk of invasive breast cancer recurrence or death compared to treatment without pertuzumab. Patent applications assigned to Genentech, Inc., and filed by inventors Mark C. Benyunes and Graham Alexander Ross further outline these therapeutic frameworks.
- Adjuvant protocols for node-positive or hormone receptor-negative early breast cancer often involve a 52-week course of intravenous pertuzumab, administered every three weeks as an initial 840 mg dose followed by 420 mg doses, alongside a 52-week course of intravenous trastuzumab utilizing an initial 8 mg/kg dose followed by 6 mg/kg doses.
- Treatment typically incorporates taxane-based chemotherapy, such as 3 or 4 cycles of 75 mg/m2 or 100 mg/m2 docetaxel every three weeks or 12 cycles of 80 mg/m2 paclitaxel weekly, alongside anthracycline-based regimens like FEC, FAC, AC, or EC (consisting of 3 or 4 cycles of 5-fluorouracil plus epirubicin plus cyclophosphamide, 5-fluorouracil plus doxorubicin plus cyclophosphamide, 4 cycles of doxorubicin plus cyclophosphamide, or epirubicin plus cyclophosphamide), with pertuzumab and trastuzumab started on Day 1 of the first taxane-containing cycle.
- These combined methods are specifically utilized to increase invasive disease-free survival at three years post-administration, including for node-positive patients who have 4 to 9 involved lymph nodes out of 4 or more involved lymph nodes.
